Discovery of novel methionine adenosyltransferase 2A (MAT2A) allosteric inhibitors by structure-based virtual screening.
Kalliokoski, T., Kettunen, H., Kumpulainen, E., Kettunen, E., Thieulin-Pardo, G., Neumann, L., Thomsen, M., Paul, R., Malyutina, A., Georgiadou, M.(2023) Bioorg Med Chem Lett 94: 129450-129450
- PubMed: 37591318 
- DOI: https://doi.org/10.1016/j.bmcl.2023.129450
- Primary Citation of Related Structures:  
8P1T, 8P1V, 8P1W, 8P4H - PubMed Abstract: 
Methionine adenosyltransferase 2A (MAT2A) has been indicated as a drug target for oncology indications. Clinical trials with MAT2A inhibitors are currently on-going. Here, a structure-based virtual screening campaign was performed on the commercially available chemical space which yielded two novel MAT2A-inhibitor chemical series. The binding modes of the compounds were confirmed with X-ray crystallography. Both series have acceptable physicochemical properties and show nanomolar activity in the biochemical MAT2A inhibition assay and single-digit micromolar activity in the proliferation assay (MTAP -/- cell line). The identified compounds and the relating structural data could be helpful in related drug discovery projects.
Organizational Affiliation: 
Orion Pharma, Orionintie 1A, 02101 Espoo, Finland. Electronic address: tuomo.kalliokoski@orionpharma.com.